Avidity Biosciences to Participate in Upcoming Investor Conferences
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company specializing in RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), announced upcoming conference participation. The company will present at the 31st Annual Credit Suisse Healthcare Conference on November 8 at 11:00 a.m. PT and the 5th Annual Evercore ISI HealthCONx Conference on November 29 at 7:30 a.m. PT. Live webcasts and event details will be available on their website. Avidity is advancing three programs in clinical development targeting various muscular dystrophies.
- None.
- None.
SAN DIEGO, Nov. 1, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the Avidity management team will be participating at the following upcoming conferences:
- 31st Annual Credit Suisse Healthcare Conference on November 8 at 11:00 a.m. PT/2:00 p.m. ET
- 5th Annual Evercore ISI HealthCONx Conference on November 29 at 7:30 a.m. PT/10:30 a.m. ET
Live webcasts of each event, up-to-date event details and an archived replay of the webcasts following each event, will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity's proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Avidity's advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is currently in Phase 1/2 development with the ongoing MARINA™ and MARINA-OLE™ trials. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is currently in Phase 1/2 development with the FORTITUDE™ trial. AOC 1044 is designed for people with Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping and is currently in Phase 1/2 development with the EXPLORE44™ trial. AOC 1044 is the first of multiple AOCs the company is developing for DMD. Avidity is also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Avidity is headquartered in San Diego, CA. For more information about our science, pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and Twitter.
Company Contact:
Kath Gallagher
kath.gallagher@aviditybio.com
(858) 401-7900
View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conferences-301664052.html
SOURCE Avidity Biosciences, Inc.
FAQ
What conferences will Avidity Biosciences (RNA) participate in November 2022?
When is Avidity Biosciences presenting at the Credit Suisse Healthcare Conference?
Where can I find the live webcasts for Avidity's conferences?
What is Aavidity Biosciences' focus in its clinical development?
What are the dates for the November conferences involving Avidity Biosciences?
